• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.

作者信息

Xia Shuai, Chan Jasper Fuk-Woo, Wang Lijue, Jiao Fanke, Chik Kenn Ka-Heng, Chu Hin, Lan Qiaoshuai, Xu Wei, Wang Qian, Wang Chao, Yuen Kwok-Yung, Lu Lu, Jiang Shibo

机构信息

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.

State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.

出版信息

Cell Res. 2022 Apr;32(4):404-406. doi: 10.1038/s41422-022-00617-x. Epub 2022 Jan 27.

DOI:10.1038/s41422-022-00617-x
PMID:35087243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8793821/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530f/8975842/75a912b78ef5/41422_2022_617_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530f/8975842/75a912b78ef5/41422_2022_617_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/530f/8975842/75a912b78ef5/41422_2022_617_Fig1_HTML.jpg

相似文献

1
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.基于肽的泛冠状病毒融合抑制剂对新冠病毒奥密克戎变异株仍保持高效力。
Cell Res. 2022 Apr;32(4):404-406. doi: 10.1038/s41422-022-00617-x. Epub 2022 Jan 27.
2
Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants.融合抑制肽广泛抑制流感病毒和 SARS-CoV-2，包括德尔塔和奥密克戎变异株。
Emerg Microbes Infect. 2022 Dec;11(1):926-937. doi: 10.1080/22221751.2022.2051753.
3
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.SARS-CoV-2 奥密克戎亚变体对泛冠状病毒融合抑制剂表现出不同的融合性，但敏感性相似。
Emerg Microbes Infect. 2023 Dec;12(1):2178241. doi: 10.1080/22221751.2023.2178241.
4
A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.棕榈酸缀合的基于肽的泛冠状病毒融合抑制剂强烈抑制 SARS-CoV-2 奥密克戎和其他关注变体的感染。
Viruses. 2022 Mar 6;14(3):549. doi: 10.3390/v14030549.
5
Identification of Potential ACE2-Derived Peptide Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational Approaches.使用计算方法鉴定 SARS-CoV-2 奥密克戎变异株治疗中潜在的 ACE2 衍生肽模拟物。
J Phys Chem Lett. 2022 Aug 18;13(32):7420-7428. doi: 10.1021/acs.jpclett.2c01155. Epub 2022 Aug 5.
6
High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1.高通量药物筛选能够鉴定出特异性靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）Delta变异株和奥密克戎/BA.1变异株不同进入途径的进入抑制剂。
Biomed Pharmacother. 2022 Jul;151:113104. doi: 10.1016/j.biopha.2022.113104. Epub 2022 May 16.
7
Targeting the Receptor-Binding Motif of SARS-CoV-2 with D-Peptides Mimicking the ACE2 Binding Helix: Lessons for Inhibiting Omicron and Future Variants of Concern.用模拟ACE2结合螺旋的D-肽靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体结合基序：抑制奥密克戎及未来关注变体的经验教训
J Chem Inf Model. 2022 Aug 8;62(15):3618-3626. doi: 10.1021/acs.jcim.2c00500. Epub 2022 Jul 24.
8
Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.奈玛特韦抗 SARS-CoV-2 变异体的体外疗效的结构基础。
J Biol Chem. 2022 Jun;298(6):101972. doi: 10.1016/j.jbc.2022.101972. Epub 2022 Apr 22.
9
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.瑞德西韦和 GS-441524 对德尔塔、奥密克戎和其他新兴的 SARS-CoV-2 变体保持抗病毒活性。
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0022222. doi: 10.1128/aac.00222-22. Epub 2022 May 9.
10
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.针对 SARS-CoV-2 奥密克戎变异株关切性的单克隆抗体临床疗效的探索性数据。
Elife. 2022 Nov 22;11:e79639. doi: 10.7554/eLife.79639.

引用本文的文献

1
Dual-targeting strategy enables extremely potent and broad inhibition of emerging MERS-related coronaviruses.双靶点策略能够对新兴的中东呼吸综合征相关冠状病毒实现极其强效且广泛的抑制。
Cell Discov. 2025 Aug 26;11(1):70. doi: 10.1038/s41421-025-00827-8.
2
Human protein interaction networks of ancestral and variant SARS-CoV-2 in organ-specific cells and bodily fluids.器官特异性细胞和体液中原始和变异的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的人类蛋白质相互作用网络。
Nat Commun. 2025 Jul 1;16(1):5784. doi: 10.1038/s41467-025-60949-1.
3
Passivating the Omicron SARS-CoV-2 variant with self-assembled nano peptides: Specificity, stability, and no cytotoxicity.

本文引用的文献

1
Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation: A new platform for synergistic oncology therapy.R848刺激驱动的病原体模拟脂质体增强肿瘤归巢：协同肿瘤治疗的新平台
Acta Pharm Sin B. 2022 Feb;12(2):924-938. doi: 10.1016/j.apsb.2021.08.018. Epub 2021 Aug 21.
2
SARS-CoV-2 Omicron variant: Characteristics and prevention.严重急性呼吸综合征冠状病毒2型奥密克戎变异株：特征与预防
MedComm (2020). 2021 Dec 16;2(4):838-845. doi: 10.1002/mco2.110. eCollection 2021 Dec.
3
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
用自组装纳米肽使奥密克戎SARS-CoV-2变体失活：特异性、稳定性和无细胞毒性。
OpenNano. 2022 Jul-Aug;7:100054. doi: 10.1016/j.onano.2022.100054. Epub 2022 Jun 30.
4
Genomic Diversity and Evolution of Identified SARS-CoV-2 Variants in Iraq.伊拉克已鉴定的新冠病毒变异株的基因组多样性与进化
Pathogens. 2024 Nov 29;13(12):1051. doi: 10.3390/pathogens13121051.
5
Advancements in the Development of Anti-SARS-CoV-2 Therapeutics.抗 SARS-CoV-2 治疗药物的研发进展。
Int J Mol Sci. 2024 Oct 9;25(19):10820. doi: 10.3390/ijms251910820.
6
Synergistic peptide combinations designed to suppress SARS-CoV-2.旨在抑制新型冠状病毒的协同肽组合。
Heliyon. 2024 Apr 29;10(9):e30489. doi: 10.1016/j.heliyon.2024.e30489. eCollection 2024 May 15.
7
COVID-19 drug discovery and treatment options.COVID-19 药物研发和治疗选择。
Nat Rev Microbiol. 2024 Jul;22(7):391-407. doi: 10.1038/s41579-024-01036-y. Epub 2024 Apr 15.
8
FEOpti-ACVP: identification of novel anti-coronavirus peptide sequences based on feature engineering and optimization.FEOpti-ACVP：基于特征工程和优化的新型抗冠状病毒肽序列的鉴定。
Brief Bioinform. 2024 Jan 22;25(2). doi: 10.1093/bib/bbae037.
9
Development of SARS-CoV-2 entry antivirals.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入抑制剂的研发。
Cell Insight. 2024 Jan 30;3(1):100144. doi: 10.1016/j.cellin.2023.100144. eCollection 2024 Feb.
10
HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor intranasal administration.靶向刺突蛋白S2亚基中HR2结构域的HR121可作为一种用于鼻腔给药的广谱新型冠状病毒抑制剂。
Acta Pharm Sin B. 2023 May 26;13(8):3339-51. doi: 10.1016/j.apsb.2023.05.030.
BNT162b2 或科兴疫苗接种者血清对严重急性呼吸综合征冠状病毒 2 奥密克戎变异株的中和作用。
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826. doi: 10.1093/cid/ciab1041.
4
The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron.假型 SARS-CoV-2 变异株奥密克戎的显著免疫逃逸。
Emerg Microbes Infect. 2022 Dec;11(1):1-5. doi: 10.1080/22221751.2021.2017757.
5
Heavily mutated Omicron variant puts scientists on alert.高度变异的奥密克戎毒株使科学家们警觉起来。
Nature. 2021 Dec;600(7887):21. doi: 10.1038/d41586-021-03552-w.
6
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.SARS-CoV-2 Delta 突变株 P681R 增强了融合性和致病性。
Nature. 2022 Feb;602(7896):300-306. doi: 10.1038/s41586-021-04266-9. Epub 2021 Nov 25.
7
Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant.SARS-CoV-2 Delta 变异株刺突蛋白介导的膜融合与免疫逃逸。
Science. 2021 Dec 10;374(6573):1353-1360. doi: 10.1126/science.abl9463. Epub 2021 Oct 26.
8
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.针对 SARS-CoV-2 及其变体的泛冠状病毒融合抑制剂的结构和功能基础及其临床前评估。
Signal Transduct Target Ther. 2021 Jul 29;6(1):288. doi: 10.1038/s41392-021-00712-2.
9
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.强效泛冠状病毒融合抑制剂抑制 SARS-CoV-2（前称 2019-nCoV）感染，该抑制剂针对病毒的刺突蛋白，具有很强的介导膜融合能力。
Cell Res. 2020 Apr;30(4):343-355. doi: 10.1038/s41422-020-0305-x. Epub 2020 Mar 30.
10
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.一种针对人冠状病毒刺突 HR1 结构域的泛冠状病毒融合抑制剂。
Sci Adv. 2019 Apr 10;5(4):eaav4580. doi: 10.1126/sciadv.aav4580. eCollection 2019 Apr.